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lence of comorbid conditions. There is substantial 1-year mean cost associated
with pediatric ADHD, even for stable responders on their pharmacotherapy. Nota-
bly, only one quarter of the cost of ADHD is due to medication.
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OBJECTIVES: To determine if IV droperidol or olanzapine, as adjuncts to midazo-
lam administration, improve sedation quality for the acutely agitated patient in the
Emergency Department (ED). METHODS: We undertook a randomised, double-
blind, placebo-controlled, double-dummy, clinical trial in three EDs (August 2009 to
March 2011). Adult patients requiring IV drug sedation for acute agitation were
enrolled. Each was randomized to receive an IV bolus of either saline (control),
droperidol (5mg) or olanzapine (5mg). This bolus was immediately followed by an
IV midazolam bolus (2.5-5mg) then additional boluses until sedation to a pre-de-
termined endpoint was achieved. The primary outcome was time to sedation.
Secondary outcomes were the need for ’rescue’ sedation and adverse events.
RESULTS: Three hundred and thirty-six patients were enrolled. The baseline char-
acteristics of the groups did not differ (p0.05). However, the median (IQR) times to
sedation (min) differed significantly (p0.001): control group 10 (4-25), droperidol 6
(3-10), olanzapine 5 (3-10). At any time point, patients in the droperidol and olan-
zapine groups were 1.6 times more likely to be sedated compared to controls:
droperidol and olanzapine group hazard ratios (95%CI) were 1.58 (1.21-2.06) and
1.64 (1.25-2.15), respectively, (p0.001). The droperidol and olanzapine groups re-
quired less rescue sedation and alternative drug use at any time after initial seda-
tion had been achieved (p0.05). The group adverse event profiles and lengths of
stay did not differ (p0.21 and 0.32, respectively). CONCLUSIONS: Droperidol or
olanzapine administration, as adjuncts to midazolam, is safe and significantly
improves sedation quality. These findings will inform best-practice for sedation of
the acutely agitated ED patient.
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OBJECTIVES: To summarize 1) mirror image studies of risperidone long-acting
injection (RIS-LAI) with respect to patient outcomes and 2) methodological weak-
nesses of this model. METHODS: Medline and Embase were searched for mirror
image studies that examined the same patients before and after switching to RIS-
LAI. We accepted clinical trials, database studies, or chart reviews. Clinical out-
comes included rates of hospitalization, duration of stay, and visits to emergency
room or outpatient clinics. Economic outcomes included cost of drugs, services, or
overall treatment. Results were analyzed descriptively. RESULTS: Twenty-three
studies were initially identified; 14 were rejected 7 were not RIS-LAI (i.e., oral RIS or
a mixture of drugs), 5 were duplicates or had overlapping results, and 2 were trials
comparing endpoint to baseline (not true mirror image studies). The 9 accepted
studies examined 2295 patients; 3 from UK (N385), 2 from USA (N1030), and 1
each from Germany (N119), New Zealand (N489), Sweden (N164), and Taiwan
(N108). Oral atypical antipsychotics were used as prior treatment in 53% of
patients, typical depots in 15%-45%, and multiple drugs in the remainder. These
papers reported 23 clinical outcomes (78% improved, 17% worse and 4% no change)
and 7 economic outcomes (71% decreased costs, 29% increased). Potential meth-
odological weaknesses include selection, measurement, and confounding biases.
The majority arise due inherent to lack of randomization. Most problematic is
channeling bias, where new drugs are selectively prescribed to failures and other
difficult cases. Selected studies had clear evidence of potential channeling bias
(severe disease, recent relapses). CONCLUSIONS: Switching to RIS-LAI was gener-
ally associated with improved patient clinical outcomes and lower costs. Channel-
ing bias needs to be avoided in mirror image analyses.
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OBJECTIVES: Although many treatments for ADHD are used off-label, in the UK,
only atomoxetine (ATX), dexamphetamine (DEX), and methylphenidate (MPH) are
licensed for use in children and adolescents. The objective of this review was to
systematically review and synthesise the existing clinical evidence, by indirectly
comparing the licensed treatments and a drug in development, lisdexamfetamine
(LDX). METHODS: A systematic review of randomised controlled clinical trials,
dated 1960 or later, in children and adolescents with ADHD that included at least
one of LDX, MPH, DEX, or ATX was performed. Network meta-analysis methods for
dichotomous outcomes were employed to evaluate treatment efficacy (response
defined by either the ADHD Rating Scale [ADHD-RS] or Clinical Global Impression–
Improvement scale [CGI-I]) and safety outcomes (all cause withdrawals [WDW] and
withdrawal due to adverse events [AEWDW]). RESULTS: The systematic review
included 32 trials, dated 2000 or later, including data on LDX, ATX, and MPH (ex-
tended release [MPH-ER], intermediate release [MPH-intR] and immediate release
[MPH-IR]). No trials for DEX meeting the inclusion criteria were found. Sufficient
data were identified for each of the outcomes: ADHD-RS, 16 trials; CGI-I, 20 trials;
WDW, 28 trials; and AEWDW, 27 trials. The efficacy relative risks (95% confidence
intervals [CI]) for LDX versus ATX were ADHD-RS, 1.41 (1.24, 1.61); CGI-I, 1.55 (1.28,
1.87); and for LDX versus MPH-ER (the most commonly used MPH formulation)
were ADHD-RS, 1.22 (1.08, 1.38); and CGI-I, 1.23 (1.04, 1.45). The safety relative risks
(95% confidence intervals [CI]) for LDX versus ATX were WDW, 0.75 (0.49, 1.17);
AEWDW, 1.72 (0.46, 6.37); and for LDX versus MPH-ER were WDW: 1.15 (0.74, 1.78),
and AEWDW: 2.70 (0.75, 9.71). CONCLUSIONS: The evidence synthesis of efficacy
favours LDX over ATX and MPH-ER for the treatment of ADHD. The analysis of
safety data proved inconclusive due to small event rates.
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OBJECTIVES: Clinical registration studies in Major Depressive Disorder (MDD) are
mostly controlled versus placebo. Regulators, clinicians, patients and payers there-
fore lack robust information to compare a new drug to the alternatives at time of
launch. Objective was to evaluate if relative antidepressant efficacy varies over
time. We evaluated the evolution of escitalopram and citalopram. METHODS: A
database of randomized-controlled trials (RCTs) of adults suffering from MDD was
built in order to provide a comprehensive assessment of antidepressant efficacy.
New-generation antidepressants launched from 1989 to 2002 and placebo were
included in this analysis. A 5-year period was chosen for the efficacy evaluation
(from 2002 to 2007). Analyses were performed on the Montgomery-Asberg Depres-
sion Scale (MADRS) adjusted mean change from baseline at 2 months (6-12 weeks)
using a Bayesian Mixed Treatment Comparison method with random effect and
Normal likelihood. Escitalopram efficacy evolution was presented as mean differ-
ence to placebo, ranking probabilities and mean rank. RESULTS: MADRS results
were reported at 2 months in 122 RCTs; 83 were selected for this analysis (excluding
treatments launched after 2002). Differences in MADRS total score versus placebo
increased from -3.39 [-5.06;-1.70] in 2002 to -3.76 [-4.63;-2.90] in 2007 for escitalo-
pram. Ranking probabilities curves for escitalopram and citalopram were mostly
overlapping in 2002, while a much clearer separation in favour of escitalopram
appeared in 2007. Mean ranks were respectively 6.8 and 6.2 in 2002; 4.4 and 7.3 in
2007 for escitalopram and citalopram. CONCLUSIONS: Escitalopram relative effi-
cacy increased from 2002 to 2007. This was mainly explained by new positive
superiority escitalopram studies. Time of launch did not appear always to be the
most appropriate to assess antidepressant efficacy mostly based on RCTs versus
placebo. Other outcomes and studies selection may have an impact on results.
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OBJECTIVES: Previous studies report varying frequency of switching and combina-
tion use of antidepressants between age groups and by socioeconomic character-
istics. The aim of this study was to analyse frequency of and predictors for combi-
nation use and switching of antidepressants in Swedish adults aged 20-34 years.
METHODS: The study population encompassed antidepressant users aged 20-34
years initiating use between January and June 2006 (n24,897). Data on filled anti-
depressants in 2006 were collected from the Swedish Prescribed Drug Register and
information on socioeconomic characteristics from Statistics Sweden. Clinical and
socioeconomic factors associated with use of at least two antidepressants and
switching were analyzed with multivariate logistic regression. RESULTS: In total,
17.1% purchased at least two antidepressant drugs. This was more common among
women, odds ratio (95% confidence interval): 1.16 (1.04 -1.28), among those who
started on mirtazapine compared to SSRIs: 2.33 (2.01-2.71), when a psychiatric care
facility issued the index prescription compared to primary care 1.19 (1.07-1.32),
among those born in Sweden with one parent born in Sweden 1.26 (1.09-1.45) and
those who had received social assistance 1.19 (1.03-1.37). It was less common when
an occupational health facility issued the index prescription 0.70 (0.53-0.94), with
declining length of follow up 0.73 (0.62-0.86), and with increasing length of educa-
tion. Among those who used at least two antidepressants, 71.6% were classified as
switchers. Switching was less common among those starting on mirtazapine: 0.69
(0.53-0.90), when the first prescription was issued in psychiatric care 0.74 (0.60-0.90)
and among individuals with at least two years of university education 0.60
(0.41-0.87). CONCLUSIONS:Almost one fifth used two or more antidepressants; the
majority was classified as switchers. Type of starting antidepressant, whether the
index prescription was issued by a psychiatric care facility and level of education
influenced use of at least two antidepressants and switching.
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COST OF METHYLPHENIDATE AND ATOMOXETINE PRESCRIBING TO CHILDREN
AND ADULTS IN SOUTH AFRICA
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OBJECTIVES: To investigate the cost of methylphenidate and atomoxetine pre-
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scribing to children and adults in a primary care patient population. METHODS: A
retrospective, cross-sectional pharmacoepidemiological study was conducted on
data of a national community pharmacy group in South Africa for 2010. All records
for methylphenidate and/or atomoxetine (ATC Code N06BA) were analysed. Pa-
tients under 18 years were labeled as children, and patients over 18 years as adults.
RESULTS: A total of 22 387 patients (70.05% children and 29.95% adults) received
one or more prescriptions for methylphenidate and/or atomoxetine during 2010. A
total of 60 370 prescriptions were dispensed (75.54% to children and 24.46% to
adults). Most adult patients (43.11%) were between 19 and 29 years of age. Nearly
three-quarters of children (71.84%) were males, compared to only 55.32% of adults.
Children received on average 2.91 prescriptions during the year and adults only
2.20. Methylphenidate accounted for 90.00% of prescriptions to children, and
94.60% to adults. The average sales value for a methylphenidate prescription was
R366.13 for children and R408.42 for adults, compared to the average cost for an
atomoxetine prescription of R582.31 for children and R653.94 for adults. There is no
generic equivalent available for atomoxetine on the South African market. The
average Prescribed Daily Dose (PDD) for methylphenidate was estimated to be 26.27
(SD15.27) mg for children and 41.86 (SD98.57) mg for adults, and the average
PDD for atomoxetine was 38.70 (SD21.45) mg for children and 65.96 (SD118.67)
mg for adults. No seasonal variation was observed for atomoxetine, but methyl-
phenidate prescribing showed peaks and troughs corresponding with the June/July
and December/January holiday periods. CONCLUSIONS: The duration of treatment
and complexity of ADHD treatment is growing, extending into adulthood. Compre-
hensive cost studies into adult ADHD are needed that include quality-of-life and
productivity factors.
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OBJECTIVES: Clinical guidelines recommend monotherapy with antidepressants
for major depression. This study examined prescription patterns and trends as well
as antidepressant polypharmacy among patients with major depression based on
the claims database of health insurance societies between 2008 and 2011 in Japan.
METHODS: Retrospective cohort (N750,000) followed up for four years was used
to identify patients (age  18) with newly diagnosed non-psychotic major depres-
sion. The prescription patterns were examined for antidepressants (first and sec-
ond generation), BZD anxiolytics and hypnotics, sulpiride, and antipsycotics. The
data were analyzed by intent-to-treat approach at month 0, 3, 6 and 12 from the
date of diagnosis. RESULTS: A total of 10,967 patients (male: 5,362, mean age:
3711) with major depression were identified. The proportion of patients pre-
scribed at least one medication was 84% (month 0), 41% (month 3), 35% (month 6)
and 23% (month12). The proportion of patients prescribed antidepressant was 56%
(month 0), 29% (month 3), 24% (month 6) and 16% (month12). BZD anxiolytic was
prescribed to 56% (month 0), 26% (month 3), 22% (month 6) and 14% (month 12) of
the cohort. BZD hypnotics were prescribed to 25% of patients at month 0. Sulpiride
was prescribed to 25%. The proportion of patients with monotherapy of antidepres-
sant was 12% (month 0). Various combinations of polypharmacy were observed.
The most common was combination of antidepressant and BZD anxiolytics (20% at
month 0). Antidepressant with both BDZ anxiolytics and BDZ hypnotics (8% at
month 0) as well as the combination of sulpiride and BZD anxiolytics (6% at month
0) were also common. CONCLUSIONS: The majority of patterns and trends of an-
tidepressant treatment did not follow the guideline recommendation. Various pat-
terns of prescriptions and polypharmacy were observed over time.
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STATES: RESULTS FROM A LARGE PRIVATELY INSURED RETROSPECTIVE
DATABASE
Clay E1, Ruby J2, Aballea S1, Zah V3
1Creativ-Ceutical, Paris, France, 2Reckitt Benckiser Pharmaceuticals, Inc./NA, Richmond, VA,
USA, 3Health Economics Consultant, Belgrade, Serbia and Montenegro
OBJECTIVES: The buprenorphine/naloxone combination has been available in a
film formulation for the treatment of opioid dependence since 2010. A clinical trial
showed that patients preferred the film to tablet formulation. Insurance claims
data were analysed to compare patient persistence with the two formulations.
METHODS: A retrospective cohort analysis was performed using medical insur-
ance claim records extracted from the Invision Datamart database. Previously un-
treated patients who initiated treatment with buprenorphine/naloxone following
the launch of film were classified in two groups according to formulation of initial
prescription. Persistence was defined as the proportion of patients continuing
treatment for at least 6 months, with possible change in formulation. RESULTS:
The film and tablet groups included 1095 and 1048 patients respectively, enrolled
over 6.45 and 8.68 months from initiation of buprenorphine/naloxone on average.
Patient characteristics were similar between groups. In the tablet group, 12.40% of
patients switched to film after 44.5 days on average. Of the patients on film, 2.74%
switched to tablet. Mean prescribed doses were 15.37 and 14.33 mg/day in film and
tablet groups. Among patients enrolled for at least 6 months from buprenorphine/
naloxone initiation, persistence rates were 63.02% in film group vs. 57.97% with
tablet. The time to treatment discontinuation was longer in the film group, with a
hazard ratio of 0.754 (p0.0002) adjusted on age, gender, region, health plan cate-
gory, co-payment proportion, and dose. CONCLUSIONS: Patients started on bu-
prenorphine/naloxone film formulation are more likely to stay on treatment than
patients treated with tablet formulation.
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OBJECTIVES: The discussion on compliance versus non-compliance exercises
many minds in ADHD. Given the potential economic impact, we investigated soci-
etal costs among compliant and non-compliant children with ADHD.METHODS: A
cross-sectional retrospective survey among parents of a child aged 6-18 (members
of the Dutch patient organization) with ADHD was conducted in September 2010.
The TiC-P questionnaire was used to collect data on medical and non-medical
resource use. Reference prices (2010) from the Netherlands were taken as unit
costs. Differences were analysed using Students’ t-tests. Compliance status was
based on parent evaluation and based on pre-defined definitions supported by
expert opinion. RESULTS: This first analysis was based on 473 and 219 children
who were compliant or non-compliant to pharmacological treatment, respectively.
Mean age was 11.2 years, 82.8% were boys. Compliance had a significant influence
on total treatment costs, with total mean monthly costs being €543 (SD € 1141) and
€879 (SD €1368) for compliant and non-compliant children, respectively (p0.001).
The most important cost items were medical consultations (23.4% vs. 26.3%),
coaching and extra support lessons at school (24.0% vs. 18.5%), skills trainings
(18.2% vs. 19.0%), and child day care (13.8% vs. 11.0%). Medication constituted 4.8%
and 2.7% of total costs. Next to compliance, regression analysis showed that co-
morbidity also had a significant influence on total treatment costs (p0.000). In a
regression model in which compliance and comorbidity were independent vari-
ables, both were significant (p0.003 and p0.000, respectively). Mean costs were
€253 and €659 (compliant vs. non-compliant) for children without comorbidity and
€669 and €950 for children with comorbidity. Adding a dummy for
comorbidity*compliance did not show a significant interaction between the two.
CONCLUSIONS: Children compliant to ADHD medication have significant lower
monthly costs compared to non-compliant children. So, effective methods to im-
prove compliance medication in this patient population may be cost-effective.
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OBJECTIVES: Due to varying survey methods and samples, annual direct cost esti-
mates for the care of major depression (MD) in Germany vary between 1264€ and
2577€ per patient in bottom-up cost analyses. To obtain more precise estimates for
costs of MD, we drew a sample from claims data of a statutory health insurance
covering approx. 11% of the German population. By accounting for levels of disease
severity and comorbidities, we (a) provide a stratified cost analysis for MD in Ger-
many and (b) explore potential bias caused by small samples or population selec-
tion criteria. METHODS: We selected a patient cohort aged 18 to 65 and not treated
for depression in the previous 6 months with (a) at least two secured diagnoses of
depression in 2010 and (b) the first depression-related service utilization between
01.01.2010 and 15.02.2010. Depression-related costs for outpatient-care, inpatient-
care, and antidepressants were analyzed for the remaining year 2010 in total and
by provider. Patients were stratified into three disease severity (ds) levels: minor/
unspecified/atypical (ds1), moderate (ds2), and severe (ds3) MD. Furthermore 128
(co)morbidity groups were analyzed. RESULTS: The sample comprised 18,139 pa-
tients with a mean of 887€ in annual direct costs for care of MD. Mean costs by
disease severity and mental comorbidity (mc) were for (ds1): n 11,978 (66%), 623€
(without/with mc 509€/737€); for (ds2): n  4,420 (24%), 1231€ (without/with mc
1056€/1601€); for (ds3): n 1741 (10%), 1838€ (without/with mc 1389€/2483€). While
mental comorbidities significantly explained higher direct costs for depression for
every provider, somatic comorbidities did not. CONCLUSIONS: Our sample re-
vealed (a) a large proportion of patients with low disease severity (ds1) and (b) large
cost differences explained by disease severity and mental comorbidities. Compa-
rable studies reporting higher mean costs for depression may possibly underrep-
resent patients with low disease severity in their sample.
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LONGITUDINAL ANALYSIS OF PATIENT LEVEL HEALTH CARE COSTS IN
PATIENTS WITH MAJOR DEPRESSIVE DISORDER TREATED WITH DULOXETINE
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OBJECTIVES: To develop and apply a longitudinal model adjusting for pre-treat-
ment covariates to examine trajectory patterns of health care costs in patients with
major depressive disorder (MDD) treated with duloxetine. METHODS: Retrospec-
tive health care cost data from Thomson Reuters MarketScan® Database for 10,987
MDD patients, aged 18-64 initiating duloxetine in 2007 at low, standard, or high
doses (60, 60, or 60 mg/day) were used to build a longitudinal model for the
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